Innovation1 Biotech Inc. (IVBT)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -5.98 Million USD | 85.35% |
| 2022 | -40.87 Million USD | -5136.94% |
| 2021 | 811.56 Thousand USD | 126.55% |
| 2020 | -3.05 Million USD | -1973.72% |
| 2019 | -147.37 Thousand USD | 51.37% |
| 2018 | -303.02 Thousand USD | -745.27% |
| 2017 | -35.85 Thousand USD | -2.41% |
| 2016 | -35 Thousand USD | -141.05% |
| 2015 | -14.52 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 FY | -5.98 Million USD | 85.35% |
| 2023 Q2 | -298.85 Thousand USD | 67.25% |
| 2023 Q3 | -298.85 Thousand USD | 0.0% |
| 2023 Q4 | -4.45 Million USD | -1390.46% |
| 2023 Q1 | -912.53 Thousand USD | -11.0% |
| 2022 Q1 | -239.85 Thousand USD | -211.88% |
| 2022 FY | -40.87 Million USD | -5136.94% |
| 2022 Q4 | -822.08 Thousand USD | 66.56% |
| 2022 Q3 | -2.45 Million USD | 6.44% |
| 2022 Q2 | -2.62 Million USD | -995.53% |
| 2021 FY | 811.56 Thousand USD | 126.55% |
| 2021 Q3 | 796.15 Thousand USD | 42.69% |
| 2021 Q2 | 557.95 Thousand USD | 335.16% |
| 2021 Q1 | -237.26 Thousand USD | 67.71% |
| 2021 Q4 | -76.9 Thousand USD | -109.66% |
| 2020 Q3 | 54.21 Thousand USD | 103.33% |
| 2020 Q2 | -1.62 Million USD | -503.91% |
| 2020 Q4 | -734.79 Thousand USD | -1455.44% |
| 2020 Q1 | -269.84 Thousand USD | -289.08% |
| 2020 FY | -3.05 Million USD | -1973.72% |
| 2019 Q3 | -22.45 Thousand USD | -270.74% |
| 2019 Q2 | 13.15 Thousand USD | 114.39% |
| 2019 Q1 | -91.4 Thousand USD | 88.74% |
| 2019 FY | -147.37 Thousand USD | 51.37% |
| 2019 Q4 | -69.35 Thousand USD | -208.83% |
| 2018 Q4 | -811.88 Thousand USD | -4179.86% |
| 2018 Q2 | -121.89 Thousand USD | -435.42% |
| 2018 Q1 | -22.76 Thousand USD | -50.12% |
| 2018 FY | -303.02 Thousand USD | -745.27% |
| 2018 Q3 | -18.97 Thousand USD | 84.44% |
| 2017 Q3 | -3975.00 USD | 15.44% |
| 2017 Q4 | -15.16 Thousand USD | -281.53% |
| 2017 FY | -35.85 Thousand USD | -2.41% |
| 2017 Q1 | -12 Thousand USD | -71.54% |
| 2017 Q2 | -4701.00 USD | 60.85% |
| 2016 Q1 | -7844.00 USD | -169.37% |
| 2016 Q4 | -7000.00 USD | 53.33% |
| 2016 Q3 | -15 Thousand USD | -190.47% |
| 2016 Q2 | -5164.00 USD | 34.17% |
| 2016 FY | -35 Thousand USD | -141.05% |
| 2015 FY | -14.52 Thousand USD | 0.0% |
| 2015 Q2 | -2034.00 USD | 0.0% |
| 2015 Q3 | -3820.00 USD | -87.81% |
| 2015 Q4 | -2912.00 USD | 23.77% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| America Great Health | -761.42 Thousand USD | -686.46% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | 30.627% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 80.525% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 95.175% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 62.755% |
| Better Therapeutics, Inc. | -39.76 Million USD | 84.939% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 68.259% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 67.416% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 83.278% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 83.396% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 94.771% |
| Evolutionary Genomics, Inc. | -2.24 Million USD | -166.351% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 91.989% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 89.864% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 71.878% |
| Molecular Templates, Inc. | -8.12 Million USD | 26.289% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | 60.544% |
| NexImmune, Inc. | -32.34 Million USD | 81.486% |
| Orgenesis Inc. | -55.36 Million USD | 89.183% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 76.296% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -7575.591% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 67.259% |
| Scopus BioPharma Inc. | -11.6 Million USD | 48.421% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 98.955% |
| Statera Biopharma, Inc. | -174.4 Million USD | 96.567% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -66.897% |
| Trevena, Inc. | -40.28 Million USD | 85.137% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -10417.908% |
| Vaccinex, Inc. | -20.25 Million USD | 70.43% |
| Vicapsys Life Sciences, Inc. | -1.18 Million USD | -406.573% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 88.272% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | 23.002% |